Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resi… Read more
Formosa Pharmaceuticals, Inc. (6838) - Net Assets
Latest net assets as of September 2025: NT$1.51 Billion TWD
Based on the latest financial reports, Formosa Pharmaceuticals, Inc. (6838) has net assets worth NT$1.51 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.11 Billion) and total liabilities (NT$595.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.51 Billion |
| % of Total Assets | 71.72% |
| Annual Growth Rate | 57.9% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 55.45 |
Formosa Pharmaceuticals, Inc. - Net Assets Trend (2021–2024)
This chart illustrates how Formosa Pharmaceuticals, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Formosa Pharmaceuticals, Inc. (2021–2024)
The table below shows the annual net assets of Formosa Pharmaceuticals, Inc. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.55 Billion | +35.77% |
| 2023-12-31 | NT$1.14 Billion | +144.03% |
| 2022-12-31 | NT$467.40 Million | +18.86% |
| 2021-12-31 | NT$393.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Formosa Pharmaceuticals, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 95140300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$3.70 Billion | 239.08% |
| Total Equity | NT$1.55 Billion | 100.00% |
Formosa Pharmaceuticals, Inc. Competitors by Market Cap
The table below lists competitors of Formosa Pharmaceuticals, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Komelon Corporation
KQ:049430
|
$65.79 Million |
|
Dry Cell and Storage Battery JSC
VN:PAC
|
$65.79 Million |
|
Samsung Pharm
KO:001360
|
$65.82 Million |
|
Nicolas Correa SA
MC:NEA
|
$65.83 Million |
|
Bharat Rasayan Limited
NSE:BHARATRAS
|
$65.75 Million |
|
Nelly Group AB
ST:NELLY
|
$65.74 Million |
|
DocGo Inc
NASDAQ:DCGO
|
$65.72 Million |
|
ERBUD S.A. INH. ZY-10
F:9DP
|
$65.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Formosa Pharmaceuticals, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,140,029,000 to 1,547,978,000, a change of 407,949,000 (35.8%).
- Net loss of 201,014,000 reduced equity.
- New share issuances of 630,449,000 increased equity.
- Other factors decreased equity by 21,486,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-201.01 Million | -12.99% |
| Share Issuances | NT$630.45 Million | +40.73% |
| Other Changes | NT$-21.49 Million | -1.39% |
| Total Change | NT$- | 35.78% |
Book Value vs Market Value Analysis
This analysis compares Formosa Pharmaceuticals, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.66x to 2.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$3.83 | NT$25.50 | x |
| 2022-12-31 | NT$3.99 | NT$25.50 | x |
| 2023-12-31 | NT$8.50 | NT$25.50 | x |
| 2024-12-31 | NT$10.25 | NT$25.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Formosa Pharmaceuticals, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -140.22%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.36x
- Recent ROE (-12.99%) is above the historical average (-57.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -102.07% | -1405.18% | 0.04x | 1.75x | NT$-440.16 Million |
| 2022 | -87.03% | -30895.21% | 0.00x | 1.88x | NT$-452.96 Million |
| 2023 | -28.24% | -1032.84% | 0.02x | 1.51x | NT$-435.96 Million |
| 2024 | -12.99% | -140.22% | 0.07x | 1.36x | NT$-355.81 Million |
Industry Comparison
This section compares Formosa Pharmaceuticals, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Formosa Pharmaceuticals, Inc. (6838) | NT$1.51 Billion | -102.07% | 0.39x | $65.78 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |